ArticleMolecular therapy : the journal of the American Society of Gene Therapy2015
A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Baboon endogenous retrovirus (ERV) envelope pseudotyped lentiviral vectors outperform human ERV lentivectors for transduction of T, B, NK and HSPCs.Gene therapy · 2026Article
- Mouse B cells engineered to express an anti-HPV antibody elicit anti-tumor T cell responses.Frontiers in immunology · 2025Article
- Engineered human B cells targeting tumor-associated antigens exhibit antigen presentation and antibody-mediated functions.Frontiers in immunology · 2025Article
- Developing a workflow for the isolation of hybridoma cells producing fully human antigen-specific antibodies using a surface IgG detection method.Scientific reports · 2024Article
- Single-hit genome editing optimized for maturation in B cells redirects their specificity toward tumor antigens.Scientific reports · 2024Article
- Evolution and synthetic biology.Current opinion in microbiology · 2023Review
- Engineering B cells with customized therapeutic responses using a synthetic circuit.Molecular therapy. Nucleic acids · 2023Article
- In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice.Nature biotechnology · 2022Article
- Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies.Cancer immunology, immunotherapy : CII · 2022Article
- Genome edited B cells: a new frontier in immune cell therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors.International journal of molecular sciences · 2021Review
- Vector Strategies to Actualize B Cell-Based Gene Therapies.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Immunotherapy perspectives in the new era of B-cell editing.Blood advances · 2021Article
- Baboon Envelope Pseudotyped "Nanoblades" Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34Frontiers in genome editing · 2021Article
- Review
- Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion.Nature communications · 2020Article
- Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration.Cell death & disease · 2020Article
- Genome Engineering of Primary Human B Cells Using CRISPR/Cas9.Journal of visualized experiments : JoVE · 2020Article
- B-cell engineering: A promising approach towards vaccine development for COVID-19.Medical hypotheses · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
The development of lentiviral vectors (LVs) for expression of a specific antibody can be achieved through the transduction of mature B-cells. This approach would provide a versatile tool for active immunotherapy strategies for infectious diseases or cancer, as well as for protein engineering. Here, we created a lentiviral expression system mimicking the natural production of these two distinct immunoglobulin isoforms. We designed a LV (FAM2-LV) expressing an anti-HCV-E2 surface glycoprotein antibody (AR3A) as a membrane-anchored Ig form or a soluble Ig form, depending on the B-cell maturation status. FAM2-LV induced high-level and functional membrane expression of the transgenic antibody in a nonsecretory B-cell line. In contrast, a plasma cell (PC) line transduced with FAM2-LV preferentially produced the secreted transgenic antibody. Similar results were obtained with primary B-cells transduced ex vivo. Most importantly, FAM2-LV transduced primary B-cells efficiently differentiated into PCs, which secreted the neutralizing anti-HCV E2 antibody upon adoptive transfer into immunodeficient NSG (NOD/SCIDγc(-/-)) recipient mice. Altogether, these results demonstrate that the conditional FAM2-LV allows preferential expression of the membrane-anchored form of an antiviral neutralizing antibody in B-cells and permits secretion of a soluble antibody following B-cell maturation into PCs in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.